Price movement over the last 24 hours
Amgen, Inc. vs Costco Wholesale Corporation — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Costco Wholesale Corporation trades at $917.59 (market cap $406.34B). The key difference: Costco Wholesale Corporation is far larger — about 2.1× Amgen, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | COST | |
|---|---|---|
Market Cap | $196.12B | $406.34B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $1.09K |
52-Week Low | $271.18 | $849.63 |
Enterprise Value | $241.41B | $394.48B |
Dividend Yield | 2.77% | 0.64% |
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Costco (COST) trades at $916.25, up 0.36% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $275.24 billion in 2025 and beat earnings expectations in recent quarters, though it missed in Q1 2026. Analyst consensus is strongly bullish with a $1,120 price target, supported by robust membership fee income and expanding margins.
The outlook remains positive due to consistent revenue growth and high analyst confidence, but risks include elevated valuation multiples and competitive pressures. The stock's current price is below the consensus target, suggesting potential upside if fundamental performance continues.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →